Non-healthcare costs of hepatitis C: a systematic review

References

• World Health Organization.Global hepatitis report, 2017 [Internet]. Geneva: World Health Organization. 2017; [Cited 2017 May 16].  A vailable from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603–1658.
   PubMed Web of Science ®Google Scholar
• Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: does sex play a role? J Infect Dis. 2014;209(SUPPL. 3):81–85.
   Web of Science ®Google Scholar
• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.
   PubMed Web of Science ®Google Scholar
• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385(9973):1124–1135.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, He T. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics. 2016;34(6):551–567.
   PubMed Web of Science ®Google Scholar
• Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis C reduces the long-term Risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig. 2015;35(12):843–850.
   PubMed Web of Science ®Google Scholar
• Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30–36.
   PubMed Web of Science ®Google Scholar
• Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730–740.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016 [Internet]. Eur Assoc Study Liver. DOI:10.1016/j.jhep.2016.09.001
   Google Scholar
• Recommendations for testing, managing, and treating hepatitis C [Internet]. AASLD-IDSA. [Updated 2017 July 5; cited 2017 May 18]  Available from: http://hcvguidelines.org
   Google Scholar
• van der Meer AJ, Maan R, Veldt BJ, et al. Association between sustained virological response and all-causemortality among patients with chronic hepatitis C and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31(6):1168–1176.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global report on access to hepatitis C treatment. Focus on Overcoming Barriers. [Internet]. Geneva: World Health Organization. 2016; [Cited 2017 May 16]. Available from: http://www.who.int/hepatitis/publications/hep-c-access-report/en/
   Google Scholar
• Ashtari S, Vahedi M, Pourhoseingholi MA, et al. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013;13(5):1–8.
   Web of Science ®Google Scholar
• Sethi N, Tapper EB, Vong A, et al. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepat. 2015;22(12):974–976.
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Bennett H, et al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One. 2015;10(1):e0117334.
   PubMed Web of Science ®Google Scholar
• Akpo EIH, Sbarigia U, Wan G, et al. Determinant factors of the direct medical costs associated with genotype 1 Hepatitis C infection in treatment-experienced patients. Drugs R D. 2015;15(4):335–349.
   PubMedGoogle Scholar
• Gordon SC, Hamzeh FM, Pockros PJ, et al. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther. 2013;38(7):784–793.
   Google Scholar
• Maan R, Zaim R, van der Meer AJ, et al. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31(11):1851–1859.
   PubMed Web of Science ®Google Scholar
• Menzin J, White LA, Nichols C, et al. The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. BMC Health Serv Res. 2012;12(1):459.
   PubMed Web of Science ®Google Scholar
• Rein DB, Borton J, Liffmann DK, et al. The burden of hepatitis C to the United States medicare system in 2009: descriptive and economic characteristics. Hepatology. 2016;63(4):1135–1144.
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rossol S, Bert F, et al. Outcomes and costs of treating hepatitis c patients in the era of first generation protease inhibitors - Results from the pan study. PLoS One. 2016;11(7):1–14.
   Web of Science ®Google Scholar
• Younossi ZM, Park H, Dieterich D, et al. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care. Med. 2016;95(41):e5048.
   PubMed Web of Science ®Google Scholar
• Vandijck D, Moreno C, Stärkel P, et al. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastroenterol Belg. 2014;77(2):285–290.
   PubMed Web of Science ®Google Scholar
• Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164–2170.
   PubMed Web of Science ®Google Scholar
• Poret AW, Ozminkowski RJ, Goetzel R, et al. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag. 2002;5(2):95–107.
   Google Scholar
• Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5):243–250.
   PubMed Web of Science ®Google Scholar
• McCombs JS, Yuan Y, Shin J, et al. Economic burden associated with patients diagnosed with hepatitis c. Clin Ther. 2011;33(9):1268–1280.
   PubMed Web of Science ®Google Scholar
• Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol. 2005;42(5):639–645.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
   Google Scholar
• Krol M Productivity costs in economic evaluations. 2012. Available from: http://repub.eur.nl/pub/38176/
   Google Scholar
• El Khoury AC, Klimack WK, Wallace C, et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012;19(3):153–160.
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ed. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington (DC): US Government Printing Office; 2008.
   Google Scholar
• Leigh JP, Bowlus CL, Leistikow BN et al. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231–2237.
   PubMedGoogle Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511.
   PubMed Web of Science ®Google Scholar
• Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436–442.
   PubMed Web of Science ®Google Scholar
• Shah BB, Wong JB. The economics of hepatitis C virus. Clin Liver Dis. 2006;10(4):717–734.
   PubMedGoogle Scholar
• Sagmeister M, Renner EL, Mullhaupt B, et al. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol. 2002;14(1):25–34.
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–1569.
   PubMed Web of Science ®Google Scholar
• Bañares E, Bárcena R, Hidalgo-Vega Á. Carga Económica y social de las enfermedades hepáticas crónicas. Compendio de publicaciones clave basado en una revisión sistemática de la literatura. Madrid: Springer Healthcare Ibérica SL; 2015.
   Google Scholar
• GDP deflator (base year varies by country) [Internet]. World Bank Natl. accounts data, OECD Natl. Accounts data files. 2017 [cited: 2017 May 10]. Available from: http://data.worldbank.org/indicator/NY.GDP.DEFL.ZS
   Google Scholar
• Current and historical rate tables [Internet]. XE;  [cited: 2017 May 10]. Available from: http://www.xe.com/currencytables/
   Google Scholar
• Brook RA, Kleinman NL, Su J, et al. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011;17(10):657–664.
   PubMed Web of Science ®Google Scholar
• El Khoury AC, Vietri J, Prajapati G. The burden of untreated hepatitis c virus infection: a US patients’ perspective. Dig Dis Sci. 2012;57(11):2995–3003.
   PubMed Web of Science ®Google Scholar
• Ruhl C, Sayer B, Byrd-Holt D, et al. Costs of Digestive Diseases. In: Everhart JE, editor. Burden of digestive diseases in the United States Report [Internet]. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008 [cited 2015 Oct 13]. Available from: https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/Pages/burden-digestive-diseases-in-united-states-report.aspx
   Google Scholar
• Younossi ZM, Jiang Y, Smith NJ, et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology. 2015;61(5):1471–1478.
   PubMed Web of Science ®Google Scholar
• Tandon N, Reddy KR, Balart L, et al. Direct and indirect cost burden of chronic hepatitis C. Am J Pharm Benefits [Internet]. 2015;7(4):e90–e100.
   Web of Science ®Google Scholar
• Baran RW, Samp JC, Walker DR, et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ [Internet]. 2015;18(9):691–703.
   PubMed Web of Science ®Google Scholar
• Vietri J, Prajapati G, El Khoury AC, et al. The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol [Internet]. 2013;13(1):16.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat. 2016;23(3):217–226.
   PubMed Web of Science ®Google Scholar
• Shiell A, Law MG. The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy (New. York). 2001;58(2):121–131.
   Web of Science ®Google Scholar
• Zare F, Fattahi MR, Sepehrimanesh M, et al. Economic burden of hepatitis C virus infection in different stages of disease: a report from Southern Iran. Hepat Mon. 2016;16(4):1–7.
   Web of Science ®Google Scholar
• Marcellusi A, Viti R, Capone A, et al. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur Rev Med Pharmacol Sci. 2015;19(9):1610–1620.
   PubMed Web of Science ®Google Scholar
• Shon C, Choi H-Y, Shim -J-J, et al. The economic burden of hepatitis A, B, and C in South Korea. Jpn J Infect Dis. 2016;69(1):18–27.
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J, Peña-Longobardo LM, Alonso S, et al. Labour productivity losses caused by premature death associated with hepatitis C in Spain. Eur J Gastroenterol Hepatol. 2015;27(6):631–636.
   PubMed Web of Science ®Google Scholar
• Patruni B, Nolte E. Hepatitis C: a projection of the healthcare and economic burden in the UK. TR1307. 2013. Available from: http://www.rand.org/pubs/technical_reports/TR1307.html.
   Google Scholar
• Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24(9):869–890.
   PubMed Web of Science ®Google Scholar
• Kavosi Z, Zare F, Jafari A, et al. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Hepat Mon. 2016;4(16):1–7.
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–184.
   PubMed Web of Science ®Google Scholar
• García-Fulgueiras A Carga de Enfermedad por Hepatitis C en España [ Doctoral thesis]. San Juan de Alicante: Universidad Miguel Hernández; 2012.
   Google Scholar
• Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56(5):1651–1660.
   PubMed Web of Science ®Google Scholar
• Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19(6):438–447.
   PubMed Web of Science ®Google Scholar
• Grant WC, Jhaveri RR, McHutchison JG, et al. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology. 2005;42(6):1406–1413.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat. 2016;23(8):623–630.
   PubMed Web of Science ®Google Scholar
• Division for Heart Disease and Stroke Prevention (Centers for Disease Control and Prevention). Economic impact analysis cost of illness: the second of a five-part series: part 2, 1–49. 2014. Available from: http://www.cdc.gov/dhdsp/programs/spha/economic_evaluation/module_ii/podcast_ii.pdf.
   Google Scholar